Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

KILLCANCER

Financiado

Cerrado

Nanobody targeted photodynamic therapy to kill cancer

Current cancer therapies often fail to cure patients. Ideally, therapy should locally eradicate cancer and should be capable of inducing long term protection, through activation of the immune system. Photodynamic therapy (PDT) is... ver más

31/12/2021

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

UNIVERSITEIT UTRECHT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-12-31

ERC-StG-2015: ERC Starting Grant

I+D

Cerrada hace 9 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

1.50M€ | Lider

BAIKOR WORLDWIDE

228.97K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

READY Getting ready to treat human patients with nanobody targeted... 150K€ Cerrado

NanoPDT Efficient Tumor Targeting and Therapy Using Near Infrared Na... 269K€ Cerrado

BIOnanoPDT Phthalocyanine biopolymeric nanoparticle delivery systems fo... 150K€ Cerrado

SAF2014-54057-R DESARROLLO DE NANOMEDICINAS PARA TERAPIAS ANTITUMORALES E IN... 242K€ Cerrado

DINAMIT Dual Imaging Nano Micro sized Theranostics against cancer 265K€ Cerrado

NANO-PEFIS A combined photoelectrochemical and fluorescence imaging sys... Cerrado

Duración del proyecto: 68 meses Fecha Inicio: 2016-04-27
Fecha Fin: 2021-12-31

Líder del proyecto

UNIVERSITEIT UTRECHT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Current cancer therapies often fail to cure patients. Ideally, therapy should locally eradicate cancer and should be capable of inducing long term protection, through activation of the immune system. Photodynamic therapy (PDT) is a treatment approach in which cancer cells are killed with compounds, named photosensitizers that are activated locally through light exposure. Importantly, PDT eradication of cancers commonly involves the immune system. However, current photosensitizers lack cancer specificity, which limits therapeutic efficacy and prolongs photosensitivity in patients. Recently, I have developed an improved version of targeted PDT that uses very small antibodies i.e. nanobodies that distribute homogenously, bind rapidly and specifically to cancer cells, and a photosensitizer that can be traced by optical imaging to guide the application of PDT. The aims of this proposal are to better understand and to advance nanobody-targeted PDT to ensure complete cancer eradication, and to facilitate its clinical translation. This will be achieved by: 1) Exploring the increased accumulation of photosensitizer through development of novel nanobody-photosensitizer conjugates to bind to cancer cells, cancer stem cells, and endothelial cells. These combinations will be evaluated for their efficacy in mice bearing human carcinomas; 2) Investigating the immune system activation to determine if, as other PDT, nanobody-targeted PDT triggers a systemic immune response, or if additional triggers are needed; 3) Studying the effect of nanobody-targeted PDT in dogs entering the veterinary clinic with oral or colorectal cancers. Treatment efficacy will be evaluated by monitoring cancer regression or disappearance. The outcome of this research will scientifically advance the new field of nanobody-targeted PDT, by providing essential information on its mechanism of action and the feasibility of this approach in human cancer patients, to ultimately improve current cancer treatment.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores